- Open Access
Exploring the extended role of the community pharmacist in improving blood pressure control among hypertensive patients in a developing setting
Journal of Pharmaceutical Policy and Practice volume 10, Article number: 39 (2017)
In most developing countries including Ghana, there is scant literature on the involvement of the community pharmacist in the care of patients with chronic conditions such as hypertension and blood pressure control. The objective of the study was to evaluate the effect of a pharmaceutical care model on blood pressure control and adherence among hypertensive patients.
This was a quasi experimental design and the primary outcome measure was a change in systolic and diastolic blood pressure. One hundred and eighty hypertensive patients were recruited for the study: 90 in the intervention group and 90 in the control group. The intervention, consisting of health education, adherence counselling and medicine use review; was offered monthly for six months.
At baseline there was no significant difference in demographic and clinical characteristics between the intervention and control group. Pharmaceutical care issues identified among the intervention group during the 6 months period were non effectiveness of therapy (n = 23), experience of side effects (n = 20) and nonadherence to therapy (n = 40). The mean diastolic blood pressure difference between the intervention group and the control group was statistically significant (p = 0.001). The mean adherence difference between the two groups was also statistically significant at the end of the study. (p = 0.001).
The pharmaceutical care intervention offered by the pharmacist led to the resolution of some pharmaceutical care issues, improvement in diastolic blood pressure and adherence among hypertensive patients. Guidelines and polices to streamline these services are needed if they are to be made available in community pharmacies in developing countries.
Hypertension is currently on the rise in most developing countries including Ghana . The crude prevalence of hypertension in rural and urban Ghana ranges from 19.3% to 54.6% and it was among the first five commonest cause of outpatient morbidity in most regions in the country [2, 3]. The lack of awareness and inadequate treatment of hypertensive patients are factors contributing to the high burden of hypertension in Ghana . The typical doctor’s review period for a Ghanaian hypertensive patient is every three months and yet blood pressure control is not adequate and patients lack information about their medicines and life style modifications . There is therefore the need for services that would improve blood pressure control and prevent complications among patients with hypertension.
Community pharmacies in Ghana are privately owned and licensed by the Pharmacy Council with a mandate to promote rational use of medicines . According to the Health Professionals Regulatory Bodies Act, a pharmacist can provide medical care as first aid during an accident and also provide treatment for illness of common occurrence when consultation with a medical practitioner or dentist is not reasonably practicable . It has, however, been observed that community pharmacies in most low income settings are often underutilized and the standard of care and services tend to be suboptimal . Currently, community pharmacists in Ghana do not normally follow up and monitor patients with chronic diseases as these often visit the pharmacies only for prescription refills.
Although studies on how the community pharmacist can assist hypertensive patients control their blood pressure have been conducted with largely positive outcomes in some developed countries such as England, United States of America and Canada, not much has been done in the developing setting [8,9,10,11]. Moreover the interventions studied and the number of times pharmaceutical care was offered to hypertensive patients by the community pharmacist varied within these studies and not all pharmaceutical care issues were reported. Duplicating similar services in Ghana would therefore require evaluating a pharmaceutical care intervention suitable for the Ghanaian community pharmacy. The information obtained would be essential for the purposes of policy initiation and planning with regard to the extended roles of community pharmacists in caring for patient with chronic diseases.
This study was carried out to evaluate the effect of a pharmaceutical care intervention on blood pressure control, adherence and adoption of healthy lifestyle practices among hypertensive patients. In addition we sought to determine the pharmaceutical care issues that are common among hypertensive patients and the level of satisfaction among hypertensive patients to whom the intervention was offered.
Study design and setting
This non-randomised controlled study was conducted in five community pharmacies, in or near the Kumasi metropolis in the Ashanti region. The design involved the generation of two comparison groups because it was not feasible to randomise individuals into treatment and control groups due to lack of logistics. The intervention was offered in three community pharmacies (the intervention group), Charma situated at Aputugya, Kama at Bomso and Bandy at Adum. The control group comprised Marrita pharmacy, situated at Dompoase-Aprabo and Royal Avenue pharmacy at Manhyia. The major activities in these pharmacies included dispensing prescription and non-prescription drugs, treating illnesses of common occurrence, counselling and drug information dissemination.
Purposive sampling to select the five pharmacies was based on the following criteria. The pharmacist should be available during pharmacy opening hours, have at least one year experience in community pharmacy practice and should be easily available for training.
Description of the intervention
The intervention offered was based on the pharmaceutical care model proposed by the American College of Clinical Pharmacists . This model consists of three principal components; identifying actual and potential medication related problems, resolving actual medication related problems and preventing potential medication related problems. Drug therapy issues were categorized into four groups. These are indication, effectiveness, safety and adherence. Based on the pharmaceutical care model, the intervention offered by the community pharmacist was monthly medicines use review, health education and adherence counselling.
Medicine use review
The objective of the review was to identify and resolve drug related problems, focusing on improper drug selection, sub therapeutic doses, over dosage, adverse drug reactions, nonadherence to therapy, drug interactions and medicines use with no indication. In resolving drug therapy problems a care plan was developed via the SOAPO model [Subjective data, Objective data, Analysis, Plan and Outcome]. The subjective data was any signs and symptoms reported by the patient. The main objective data considered was the blood pressure and body mass index measurements. Based on the objective and subjective data; and medication history, an assessment of the medication related problem was made. The plan mainly consisted of recommended therapy, goals of therapy; counselling and monitoring. Patients and other health workers were involved in these plans. Patients were informed about all the necessary actions in the care plan and recommendations for medication regimen change; and elevated blood pressure was communicated to a doctor. In hypertensive patients without diabetes the targeted blood pressure was less than or equal to 140/90. In diabetic hypertensive patients the targeted blood pressure level was less than 130/80.
A concordant approach was used in educating the patient; thus patients’ views and suggestions was considered before conclusions were drawn. Patients were also educated on the common side effects of their antihypertensive medication, precautionary measures associated with taking their medicines, individualized healthy life style practices that would help in controlling their blood pressure and consequences of not adhering to their therapy. Life style practices discussed included physical activity, diet (in particular sodium reduction and a diet rich in fruits and vegetables and less fat), weight loss management, reducing alcohol intake and smoke cessation.
Two strategies were used in improving patient adherence. Dissemination of knowledge (making sure that the patient was aware of the name, dosage, side effects and purpose of their medicines) and simplifying dosage regimen.
A two day taught and practical training programme was given to the three pharmacists in the intervention group. The topics covered included pathophysiology, prevalence, risk factors, causes, diagnosis, and complication of hypertension. Goals of therapy, pharmacological methods available for managing hypertension, factors to be considered when choosing an appropriate therapy, and medicines available for the management of hypertension. Development of pharmaceutical care plans (SOAPO model), description of the pharmacist led hypertension pharmaceutical care service and procedures and protocols used in the project were also taught. Pharmacists in the control group were taught only the study procedures in the recruitment of subjects, and measurement of blood pressure and body mass index.
Hypertensive patients diagnosed for at least six months with a review period of at least two months were included in the study. The only co-morbid condition included was diabetes. Other hypertensive patients with comorbid conditions such as heart failure, stroke, and ischaemic heart disease, renal and liver diseases were excluded from the study. Furthermore pregnant women, patients with no contact numbers and patients who would not be able to return to the pharmacy for a scheduled visit were excluded from the study.
Sample size & sampling
The formula proposed by Charan & Bisawa, for calculating sample for size interventional studies [13, 14] yielded a sample of 180 hypertensive patients. Purposive sampling was used to select the first 180 patients who were within the inclusion criteria. Ninety patients were recruited into the control group: 45 patients from each of the two pharmacies; and ninety patients into the intervention Group. (IG): 30 from each of the three community pharmacies.
Identification & recruitment
Eligible hypertensive patients were identified when they visited the pharmacy with a refill prescription that had a diagnosis of hypertension. The blood pressure was measured at the pharmacy with an automated Sphygmomanometer to ensure that about 50% of the total study sample in both the intervention and control group had blood pressure levels above 140/90. When recruited the purpose and design of the study were also explained to the patient by the pharmacist. Patients then appended their signature or thumb print to a consent form if they agreed to be part of the study.
The following outcomes were assessed at baseline and at the end of the study in both groups. However outcome 7 and 9 were assessed in only the intervention group (Table 1).
Data were collected at baseline and then after 6 months for the control group. In the intervention group, the pharmacist initially interacted with the patient and offered the pharmaceutical care services described above. Information documented at baseline for both groups were: demographic characteristics, medication history (current medicines for the management of hypertension and other Over The Counter drugs and alternative medicines), life style practices (smoking status, frequency of exercise, alcohol use, consumption of salt), awareness of the name, dosage, frequency, side effect and purpose of antihypertensive prescribed and awareness of healthy lifestyle modification for managing blood pressure. Other information documented were blood pressure, body mass index measurement and level of adherence to antihypertensive medication. Additional information documented for the intervention group were pharmaceutical care issues and solutions offered. Follow up dates for subsequent visits were agreed with the patients and SMS messages were sent to remind patients of these dates. If patients failed to show up, a call was made to ascertain why the appointment was missed and a new follow up date was agreed. Patients with drug therapy related problems that needed change in therapy were referred to their normal review clinic.
During the intervention group’s monthly visits, the pharmacist had a 10–30 min face-to-face consultation with the patient. In the consultation the pharmacist measured the patients’ blood pressure and BMI. Identified drug related problems were discussed with the patient and a concordant solution sought. After the sixth month the same information documented at baseline was determined in the two groups.
For the patient satisfaction survey, a semi structured questionnaire was used to conduct a face to face interview among the 75 hypertensive patients in the intervention group after the sixth month. The questionnaire captured data on patient satisfaction with the medication use review service, health education and adherence counselling. Questions on client’s satisfaction with the overall services provided by the pharmacist and if pharmacist should be paid for offering the service were open ended questions. All other question where closed ended.
Pharmacists who offered the intervention were remunerated over the study period.
Descriptive statistics in SPSS Version 16 were used to analyse baseline demographic and clinical data. Patients who did not exercise or patients who exercised less than 30 min per day, in less than 3 days were coded as ‘no exercise’. Participant who drank more than 2 drinks per day for men and more than 1 drink per day for women were considered as regular users of alcohol.
Adherence to antihypertensive medication was measured with the Morisky self-reported scale. A ‘yes’ answer attracted a score of Zero (0) and a ‘no’ answer a score of one. Patients who scored 8 were considered highly adherent, a score of 6- < 8 was classified as medium adherence and a score below 6 was classified as low adherence. The paired sample T test was used to compare means of end of study outcomes (SBP, DBP, adherence and BMI) within the IG and the CG. McNemar test was run to determine if there was any difference in the proportion of subjects who ate salty food, consumed alcohol and exercised pre and post intervention. The general linear model (repeated measures) analysis was run to compare the difference (SBP, DBP, adherence and BMI) between the two groups at baseline and after 6 months. Then the Wilks Lambda test was used to determine if there was any differences between the two groups. The Fishers exact test of association was employed to determine any association between the intervention offered and achievement of blood pressure goal. Cramer’s V test was used to determine the strength of the association; values of 0–0.30 were considered weak, 0.31–0.70 moderate, and 0.71–1.0 strong. In the analysis of data, all p values less than 0.05 were deemed significant.
One hundred and eighty hypertensive patients were recruited. Eight patients in the intervention group dropped out of the study because they moved out of the region while 6 patients were not reachable for subsequent follow-ups. Nineteen patients in the control group were unreachable for follow up after the 6th month. Participants who finally completed the study were thus 75 and 71 for the intervention and control groups respectively.
Demographics characteristics of subjects at baseline
The mean age for the intervention group was 56.56 ± 9.197 whiles that for the control group was 53.45 ± 8.299. There was no significant difference in demographic characteristics of the two groups at baseline (Table 2).
Drug therapy problems identified among the intervention group and solutions provided
Pharmaceutical care issues identified were related to effectiveness of therapy, side effects and adherence to therapy. Tables 3, 4 and 5, illustrate the various categories of pharmaceutical problems and actions taken to resolve them. The mean time spent in offering the pharmaceutical care to hypertensive patients was 14.88 mins ±3.78818 (Range10–32 min).
Outcome measures after 6 months follow up
There was an association between the intervention and the mean SBP: both groups showed a decrease in SBP at the end of the study. However the mean SBP difference between the two groups for the time period was not statistically significant. (F = 101.569, p = 0.697 partial η2 = 0.001). There was an association between the intervention and the mean DBP during the time period: the intervention group showed a decrease in DBP and the control group showed an increase in DBP at the end of the study (Table 6). The mean DBP difference comparing the two groups was significant. (F = 20.250, p = .000 partial η2 = .123) There was also a statistically significant association between the intervention offered and attainment of BP goal [OR, 2.509 95% CI, 1.683–3.739, p = 0.21] however the association was weak (=φ .177). There was an association between the intervention and adherence, the intervention group showing an increase in mean adherence score and the control group showing a decrease in adherence scores at the end of the study. The difference in the mean adherence scores between the two groups was statistically significant. [F = 218. 851, p = .000 partial η2 = 0.228].
Patient satisfaction with intervention
Patients were satisfied with the medicines use review and health education conducted by the pharmacists. As some patients put it. Seventy three percent of patients within the intervention group were most of the time satisfied with the service provided by the pharmacist (Table 7).
The pharmacist explains the possible side effects that my medication may cause and also the service has helped me in taking my medicines. P1
The pharmacist makes sure that I understand how to take my medication and if I have a question about my medicines the pharmacist is always available to help me. P2
I am very satisfied with the service offered by the pharmacist, the advice given by the pharmacist has helped me change some unhealthy life style practices. P3
However there was some mixed opinions on whether the pharmacists should be paid for offering the service.
The pharmacist should be paid for offering such a service and this service should be provided to all hypertensive patient P4
Although the service provided by the pharmacist has helped me in taking my medicines, I cannot regularly pay for such a service. P5
Pharmaceutical care issues identified among the pharmacist intervention group and solutions provided
The common care issues identified was nonadherence to antihypertensive therapy. These were missed doses, lack of medicines and missed doctor’s appointments. Some studies among hypertensive patients have also reported nonadherence as a major care issue commonly encountered . Another category of pharmaceutical problems reported was experiencing side effects of the antihypertensive; an issue often associated with chronic diseases . Solutions provided were mostly changes in therapy because if patients continued experiencing side effects it was likely they would not take their medicines.
Low dose aspirin is an antiplatelet and its long term use is associated with major gastrointestinal and extracranial bleeding . Patients whose blood pressure are not optimised are at risk of complications such as stroke and this could be haemorrhagic if patients are on low dose aspirin. Therefore low dose aspirin is recommended for the primary prevention of cardiovascular events in hypertensive patients aged over 50 years with a baseline CVD risk level > 20% and whose blood pressure has been controlled to an audit standard of 150/90 . However some subjects were still on dispersible aspirin although their blood pressure was not controlled.
Another drug therapy problem encountered was the use of beta blockers as monotherapy in the management of hypertension. Beta blockers are often recommended as add on therapy when drugs such as diuretics and calcium channel blockers have not worked [19, 20]. Compared with placebo beta blockers are effective in reducing the blood pressure, however the blood pressure lowering efficacy of beta blockers are suboptimal compared to other antihypertensive. Furthermore there is evidence suggesting that beta blockers do not reduce mortality .
Outcome measures after 6 months
The intervention studied led to a statistically significant mean DBP difference between the IG and the CG and there was an association between the intervention offered and achievement of BP Goal. Thus, subjects who were offered the intervention were more likely to achieve BP Goal than those who were not. A similar intervention (medicines review, adherence and counselling) for 118 hypertensive patients in a randomized study in Canada caused a significant reduction in SBP in the intervention group compared to placebo. The difference in the number of subjects who had their blood pressure controlled was also statistically significant. The average age of participants, 58 years, was similar to that in our study . Achievement of BP control is essential as there is evidence that suggests that patients whose blood pressure is controlled to less than 140/90 often have a low incidence of cardiovascular complications such as stroke, myocardial infarction and death .
The mean adherence difference between the IG and the CG was also statistically significant and there was a moderate association between the intervention offered and adherence. Thus subjects who were offered the intervention were more likely to adhere to treatment than those who were not. Some studies on pharmacist intervention on adherence have shown similar or conflicting results. There was a significant difference in adherence level in the intervention and control groups in randomised studies in Thailand and United Kingdom [8, 10]. However another randomized controlled study showed no significant difference in adherence between the intervention and control groups .
Implications of findings on practice
At baseline adherence levels of subjects in both groups was quite low. It is therefore essential that measures and polices are established to achieve high adherence levels among hypertensive patients. In most clinical settings in Ghana hospital folders lack documentation of adherence to therapy for patients with chronic diseases. Ideally adherence to medication should be assessed in the consultation room during each review visit before decisions on medicines are taken. In addition, adherence could also be assessed by the pharmacist before medicines are dispensed. This practice could enable these health care personnel to identify and address any adherence concerns of the patient.
The Ghanaian community pharmacist should be encouraged to monitor and offer similar interventions to patients with hypertension who come to refill their medications; as this can improve blood pressure control and adherence and enhance the public image of the pharmacy profession in the country. For such pharmaceutical services to be effectively rolled out in Ghanaian community pharmacies it is very important for some laws and policies to be updated. For instance the Ghana Pharmacy Act 489, (1994) which has been repealed and subsumed by the Health Professions Regulatory Bodies Act 867, is silent on the extended responsibilities of the community pharmacists for patients with chronic diseases . The Pharmacy Council, Ghana in conjunction with the Community Pharmacy Pharmacist Association (CPPA) of Pharmaceutical Society of Ghana (PSGH) could determine policy guidelines on care services the community pharmacist can provide. However there is the need to explore measure to reduce the number of patients lost to follow up because pharmacy owners might not want to invest their time in offering such a service if clients are going to disappear.
Offering the intervention described in this study, is time consuming. The mean time spent with subjects was fourteen minutes and several phone calls and SMS were made in an attempt to remind them of follow up dates. It is therefore essential that the pharmacist is offered some remuneration as was done in the study and also there is the need to explore the cost effectiveness of the service. Over half of hypertensive patients agreed that the pharmacist should be paid for rendering such services and should offer it to all hypertensive patients. In the United Kingdom the community pharmacist is mandated to offer so many pharmaceutical services apart from their primary role and are paid a commission by the National Health Service (NHS) for each care service they offer .
Limitations of the study
Some patients in the Control Group (CG) were mostly lost to follow up, probably because the first follow up occurred six months after the first encounter. Another reason why follow up appointments were missed was that in some instances the telecommunication coverage was poor, hence some clients were unreachable. The study also assumed that all patients who liked salty food consumed salty food. Furthermore a quasi-experiment design was chosen for the evaluation of the pharmaceutical care of hypertensive patients instead of a randomised controlled study which is the gold standard due to the lack of documentation of clients medical and medication history in the community pharmacy.
It is feasible for Ghanaian community pharmacists to extend their services and continually offer pharmaceutical care (conducting medication reviews, assessing adherence and counselling) to patients with hypertension. This could lead to the identification and resolution of drug related problems and improvement in blood pressure control and adherence. However, for community pharmacies to effectively and continually offer these services, national policies would have to be enacted to provide some remuneration for the service. Community pharmacists in low income countries with increasing low levels of blood pressure control could adopt such an intervention. However, it is important that they consider their pharmacist staffing level and pharmacy setting. This is because this service requires the continuous presence of a pharmacist and space for offering pharmaceutical care to ensure privacy.
Body Mass Index
Community Pharmacists Association
Diastolic Blood Pressure
Pharmaceutical Society of Ghana
Systolic Blood Pressure
Subjective, Objective, Analysis, Plan and Outcome
Statistical Package for social sciences
Guwatudde D, Nankya-Mutyoba J. Kalyesubula. BMC Public Health. 2015;15:1211. https://doi.org/10.1186/s12889-015-2546-z
Bosu WK. Epidemic of hypertension in Ghana: a systematic review. BMC Public Health. 2010;10:418.
Awuah RB, Anarfi JK, Agyemang C, Ogedegbe G, Aikins AD. Prevalence, awareness, treatment and control of hypertension in urban poor communities in Accra, Ghana. J Hypertens. 2014;32(suppl 6):1203–10.
Addo J, Agyemang C, Smeeth LA, De-Graft Aikins A, Edusei AK, Ogedegbee O. Review of population-based studies on hypertension in Ghana. Ghana Medical Journal. 2012;46(suppl 2):4–11.
Marfo AFA, Owusu-Daaku FT, Opare Addo MNA, Saana IB. Ghanaian hypertensive patients understanding of their medicines and life style modification for managing hypertension. Int J Pharm Pharm Sci. 2014;4:165–70.
Parliament of Ghana Health Professions Regulatory Bodies Act 857 Part four Establishment of the Pharmacy Council [Available at URL: http://www.pcghana.org/wp-content/uploads/2017/02/Health-Professions-Regulatory-Bodies-Act.pdf Accessed: 17 July 2014.
Smith F. The quality of private pharmacy services in low and middle-income countries: a systematic review. Pharm World Sci 2009;31Suppl 3:351–361.
Sookaneknun P, Richards RME, Sanguansermsri J. Pharmacist involvement in primary care improves hypertensive patient clinical outcomes. Ann Pharmacother. 2004;38:2023–8.
Zillich AJ, Sutherland JM, Kumbera PA. Hypertension outcomes through blood pressure monitoring and evaluation by pharmacists. (HOME study). J Gen Intern Med. 2005;20:1091–6.
Blenkinsopp A, Phelan M, Bourne J, Dakhil N. Extended adherence support by community pharmacists for patients with hypertension: a randomised controlled trial. Int J Pharm Pract. 2000;8:165–75.
Chabot I, Moisan J, Grégoire JP, Milot A. Pharmacist intervention program for control of hypertension. Ann Pharmacother. 2003;37:1186–93.
American College of Clinical Pharmacist. Clinical Pharmacy Practice Model Available at https://www.accp.com/docs/report/0612_table1.pdf Accessed 12 February 2012.
Charan J, Biswas T. How to calculate sample size for different study designs in medical research. Indian Journal of Psychological Medicine. 2013;35(2):121.
Kasiulevicius V, Sapoka V, Filipaviciute R. Sample size calculation in epidemiological studies. Gerontology. 2006;7:225–31.
Chua SS, Kok LC, Yusof FAM, Tang GH, Lee SWH, Efendie B, Paraidathathu T. Pharmaceutical care issues identified by pharmacists in patients with diabetes, hypertension or Hyperlipidaemia in primary care settings. BMC Health Serv Res 2012; 12Suppl 1: 388.
Oparah AC, Adje DU, Enato FEO. Evalution of pharmaceutical care intervention to hypertensive patients in a Nigerian community pharmacy international journal. Pharm Pract. 2006;14:115–22.
NICE Hypertension: Clinical Management of Primary Hypertension in Adults Available at https://workspace.imperial.ac.uk/ref/Public/UoA%2002%20-%20Public%20Health,%20Health%20Services%20and%20Primary%20Care/NICE%20hypertension%20guidelines.pdf. Accessed on 12 July 2013.
BHS. The Use of Aspirin in Primary Prevention of Cardiovascular Disease [Available at http://www.bhsoc.org/pdfs/Statement%20on%20Aspirin%20Jan10.pdf Accessed 14 September 2014].
Chobdanian AV, Barkis GL, Black HR. The seventh report of the joint National Committee on prevention, detection evaluation and treatment of high blood pressure. Journal of American Medical Association. 2003;289:2560–72.
Messerli FH, Grossman E, Goldbourt U. Are Beta-blockers efficacious as first-line therapy for hypertension in the elderly a systematic review. Journal of American Medical Association. 1998;279:1903–7.
Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding Bendroflumethiazide as required, in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomized Control Trail. Lancet. 2005;366:895–906.
Ontario Pharmacists Association and Green Shield Canada. Impact of Community Pharmacist Interventions in Hypertension Management on Patient Outcomes: A Randomized Controlled Trial Available at https://www.opatoday.com/Media/Default/Reports/Hypertension%20Study%20-%20Final%20Report%20(January%208%202014).pdf. Accessed 10 January 2015.
NHS Community Pharmacy services a Summary Available at http://psnc.org.uk/wp-content/uploads/2013/08/CPCF-summary-July-2013.pdf. Accessed 10 October 2014.
All community pharmacies, pharmacists and hypertensive patients who agreed to be part of the study.
The work was partially funded by the Commonwealth Pharmacists Association. (CPA).
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
Ethical clearance was sought and granted by the Committee on Human Research Publications and Ethics, Kwame Nkrumah University of Science and Technology, School of Medical Sciences and Komfo Anokye Teaching Hospital, Kumasi, Ghana. Hypertensive patients who agreed to be part of the study appended their signature or thumb print to a consent form.
Consent for publication
This was part of the ethical clearance granted by Committee on Human Research Publications and Ethics, Kwame Nkrumah University of Science and Technology, School of Medical Sciences and Komfo Anokye Teaching Hospital, Kumasi, Ghana.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Marfo, A.F.A., Owusu-Daaku, F.T. Exploring the extended role of the community pharmacist in improving blood pressure control among hypertensive patients in a developing setting. J of Pharm Policy and Pract 10, 39 (2017). https://doi.org/10.1186/s40545-017-0127-5
- Pharmaceutical care
- Blood pressure